Download PDF
Klin Padiatr 2015; 227(06/07): 314-321
DOI: 10.1055/s-0035-1559664
Review
© Georg Thieme Verlag KG Stuttgart · New York

Pediatric Nodular Lymphocyte-predominant Hodgkin Lymphoma: Treatment Recommendations of the GPOH-HD Study Group

Noduläres Lymphozyten-prädominantes Hodgkin-Lymphom im Kindes- und Jugendalter: Therapieempfehlungen der GPOH-HD Studiengruppe
C. Mauz-Körholz
1   Klinik für Kinder- und Jugendmedizin, Martin-Luther-Universität Halle/ Wittenberg, Halle/ Saale, Germany
,
T. Lange
1   Klinik für Kinder- und Jugendmedizin, Martin-Luther-Universität Halle/ Wittenberg, Halle/ Saale, Germany
,
D. Hasenclever
2   Institut für Medizinische Informatik, Statistik & Epidemiologie (IMISE), Universität Leipzig, Leipzig, Germany
,
B. Burkhardt
3   Clinic for Pediatric Hematology and Oncology, University Hospital Münster, Münster, Germany
,
A. C. Feller
4   Institute for Pathology, University Hospital Schleswig-Holstein, Lübeck, Germany
,
W. Dörffel
5   Clinic for Pediatric and Youth Medicine, Helios Hospital Berlin-Buch, Berlin, Germany
,
R. Kluge
6   Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Leipzig, Leipzig, Germany
,
D. Vordermark
7   Clinic and Policlinic for Radiation Therapy, University Hospital Halle (Saale), Halle (Saale), Germany
,
D. Körholz
1   Klinik für Kinder- und Jugendmedizin, Martin-Luther-Universität Halle/ Wittenberg, Halle/ Saale, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
10 September 2015 (online)

Also available at
    Permissions and Reprints

Abstract

Nodular lymphocyte-predominant Hodgkin lymphoma (nLPHL) is a very rare disease in childhood and adolescence. In Germany, about 15 newly diagnosed patients present with this disease annually; this number comprises less than 10% of all pediatric Hodgkin lymphoma cases. Since the EuroNet-PHL-LP1 trial for early stage nLPHL patients stopped recruiting in Germany in October 2014, the GPOH-HD writing committee reviewed the literature and decided to deliver treatment recommendations for childhood and adolescent nLPHL patients. These guidelines shall be applicable to young nLPHL patients in European countries that will no longer be able to participate in nLPHL trials for young patients. Therefore, the EuroNet-PHL-nLPHL-registry will be installed to provide quality assured central review of staging and response assessment for registered patients by the Central Review Board of EuroNet-PHL in Halle/Leipzig, Germany.

Zusammenfassung

Das noduläre Lymphozyten-prädominante Hodgkin-Lymphom (nLPHL) ist eine sehr seltene Erkrankung im Kindes- und Jugenedalter mit ca. 15 Neuerkrankungen pro Jahr in Deutschland. Das sind weniger als 10% aller Hodgkin-Lymphome in dieser Altersgruppe. Die Rekrutierung für die EuroNet-PHL-LP1-Studie für Patienten mit frühen Stadien des nLPHL wurde im Oktober 2014 in Deutschland beendet. Deshalb führte die GPOH-HD-Studiengruppe einen Literaturreview durch und erstellte darauf basierend Therapieempfehlungen für nLPHL-Patienten im Kindes- und Jugendalter. Diese Empfehlungen sollen für alle Patienten in europäischen Zentren gelten, welche nicht mehr an nLPHL-Studien für diese Altersgruppe teilnehmen können. Zur Qualitätssicherung wird das EuroNet-PHL-nLPHL-Register eingerichtet. Hierbei stellt das Central Review Board der EuroNet-PHL in Halle/Leipzig für alle registrierten Patienten die Referenzbegutachtung der Bildgebung zur Stadienfestlegung und zur Beurteilung des Ansprechens auf die Therapie sicher.

Key words

Hodgkin lymphoma - NLPHL - treatment - children and adolescends - lymphocyte predominant Hodgkin lymphoma - pediatric

Schlüsselwörter

Hodgkin-Lymphom - NLPHL - Therapie - Kinder und junge Erwachsene - Lymphozyten-prädominantes Hodgkin Lymphom - pädiatrisch
 

  • References

  • 1 Advani RH, Horning SJ, Hoppe RT et al. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol 2014; 32: 912-918
    CrossrefPubMedGoogle Scholar
  • 2 Al-Mansour M, Connors JM, Gascoyne RD et al. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. J Clin Oncol 2010; 28: 793-799
    CrossrefPubMedGoogle Scholar
  • 3 Antoch G, Behringer K, Böll B et al. Hodgkin Lymphom: S3-Leitlinie Diagnostik, Therapie und Nachsorge des Hodgkin Lymphoms bei erwachsenen Patienten. (Version 1.0) 2013
    PubMedGoogle Scholar
  • 4 Appel BE, Chen L, Buxton A et al. Impact of low-dose involved-field radiation therapy on pediatric patients with lymphocyte-predominant Hodgkin lymphoma treated with chemotherapy: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2012; 59: 1284-1289
    CrossrefPubMedGoogle Scholar
  • 5 Appel BE, Ehrlich P, Chen L et al. Treatment of pediatric stage IA lymphocyte-predominant Hodgkin lymphoma with surgical resection alone: A report from the Children’s Oncology Group. J Clin Oncol 2012; (30 Suppl) Abstract 9524
    PubMedGoogle Scholar
  • 6 Biasoli I, Stamatoullas A, Meignin V et al. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer 2010; 116: 631-639
    CrossrefPubMedGoogle Scholar
  • 7 Chen RC, Chin MS, Ng AK et al. Early-stage, lymphocyte-predominant Hodgkin’s lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol 2010; 28: 136-141
    CrossrefPubMedGoogle Scholar
  • 8 Dörffel W, Rühl U, Lüders H et al. Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95. J Clin Oncol 2013; 31: 1562-1568
    CrossrefPubMedGoogle Scholar
  • 9 Eichenauer DA, Engert A, André M et al. Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25 (Suppl. 03) iii70-iii75 DOI: 10.1093/annonc/mdu181.
    CrossrefPubMedGoogle Scholar
  • 10 Eichenauer DA, Fuchs M, Pluetschow A et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood 2011; 118: 4363-4365
    CrossrefPubMedGoogle Scholar
  • 11 Fanale MA, Lai C, McLaughlin P et al. Outcomes of Nodular Lymphocyte Predominant Hodgkin’s Lymphoma (NLPHL) Patients Treated with R-CHOP Blood (ASH Annual Meeting Abstracts) 2010; 116 Abstract 2812
    PubMed
  • 12 Fan Z, Natkunam Y, Bair E et al. Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol 2003; 27: 1346-1356
    CrossrefPubMedGoogle Scholar
  • 13 Grellier JF, Vercellino L, Leblanc T et al. Performance of FDG PET/CT at initial diagnosis in a rare lymphoma: nodular lymphocyte-predominant Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2014; 41: 2023-2030
    CrossrefPubMedGoogle Scholar
  • 14 Hall GW, Katzilakis N, Pinkerton CR et al. Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma – a Children’s Cancer and Leukaemia Group report. Br J Haematol 2007; 138: 761-768
    CrossrefPubMedGoogle Scholar
  • 15 Harris NL, Jaffe ES, Diebold J et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 1999; 10: 1419-1432
    CrossrefPubMedGoogle Scholar
  • 16 Hartmann S, Eichenauer DA, Plütschow A et al. The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood 2013; 122: 4246-4252 quiz 4292
    CrossrefPubMedGoogle Scholar
  • 17 Hartmann S, Eichenauer DA, Plütschow A et al. Histopathological features and their prognostic impact in nodular lymphocyte-predominant Hodgkin lymphoma–a matched pair analysis from the German Hodgkin Study Group (GHSG). Br J Haematol 2014; 167: 238-242
    CrossrefPubMedGoogle Scholar
  • 18 Hodgson DC. Late effects in the era of modern therapy for Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2011; 323-329
    PubMedGoogle Scholar
  • 19 Hoppe RT, Advani RH, Ai WZ et al. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012; 10: 589-597
    PubMedGoogle Scholar
  • 20 Karayalcin G, Behm FG, Gieser PW et al. Lymphocyte predominant Hodgkin disease: clinico-pathologic features and results of treatment–the Pediatric Oncology Group experience. Med Pediatr Oncol 1997; 29: 519-525
    CrossrefPubMedGoogle Scholar
  • 21 Karuturi M, Hosing C, Fanale M et al. High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma. Biol. Blood Marrow Transplant. 2013; 19: 991-994
    CrossrefPubMedGoogle Scholar
  • 22 Körholz D, Wallace WH, Landman-Parker J. EuroNet-Paediatric Hodgkin’s Lymphoma Group (EuroNet-PHL-LP1): First international inter-group study for nodular lymphocyte-predominant Hodgkin’s lymphoma in children and adolescents. NCT01088750 http://cancer.gov/clinicaltrials/EURONET-PHL-LP1
    PubMedGoogle Scholar
  • 23 Kurch L, Mauz-Körholz C, Bertling S et al. The EuroNet Paediatric Hodgkin Network – Modern Imaging Data Management for Real Time Central Review in Multicentre Trials. Klin Padiatr 2013; 225: 357-361
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Mauz-Körholz C, Gorde-Grosjean S, Hasenclever D et al. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer 2007; 110: 179-185
    CrossrefPubMedGoogle Scholar
  • 25 Mauz-Körholz C, Hasenclever D, Dörffel W et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol 2010; 28: 3680-3686
    CrossrefPubMedGoogle Scholar
  • 26 Nogová L, Reineke T, Brillant C et al. Lymphocyte-predominant and classical Hodgkin’s lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008; 26: 434-439
    CrossrefPubMedGoogle Scholar
  • 27 Nogová L, Reineke T, Eich HT et al. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 2005; 16: 1683-1687
    CrossrefPubMedGoogle Scholar
  • 28 Pellegrino B, Terrier-Lacombe MJ, Oberlin O et al. Lymphocyte-predominant Hodgkin’s lymphoma in children: therapeutic abstention after initial lymph node resection – a Study of the French Society of Pediatric Oncology. J Clin Oncol 2003; 21: 2948-2952
    CrossrefPubMedGoogle Scholar
  • 29 Sandoval C, Venkateswaran L, Billups C et al. Lymphocyte-predominant Hodgkin disease in children. J Pediatr Hematol Oncol 2002; 24: 269-273
    CrossrefPubMedGoogle Scholar
  • 30 Savage KJ, Skinnider B, Al-Mansour M et al. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood 2011; 118: 4585-4590
    CrossrefPubMedGoogle Scholar
  • 31 Schlembach PJ, Wilder RB, Jones D et al. Radiotherapy alone for lymphocyte-predominant Hodgkin’s disease. Cancer J 2002; 8: 377-383
    CrossrefPubMedGoogle Scholar
  • 32 Schulz H, Rehwald U, Morschhauser F et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008; 111: 109-111
    CrossrefPubMedGoogle Scholar
  • 33 Shankar A, Daw S. Nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents – a comprehensive review of biology, clinical course and treatment options. Br J Haematol 2012; 159: 288-298
    CrossrefPubMedGoogle Scholar
  • 34 Shankar A, Hall GW, Gorde-Grosjean S et al. Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin’s lymphoma – an Anglo-French collaborative report. Eur J Cancer 2012; 48: 1700-1706
    CrossrefPubMedGoogle Scholar
  • 35 Sohani AR, Jaffe ES, Harris NL et al. Nodular lymphocyte-predominant hodgkin lymphoma with atypical T cells: a morphologic variant mimicking peripheral T-cell lymphoma. Am J Surg Pathol 2011; 35: 1666-1678
    CrossrefPubMedGoogle Scholar
  • 36 Venkataraman G, Raffeld M, Pittaluga S et al. CD15-expressing nodular lymphocyte-predominant Hodgkin lymphoma. Histopathology 2011; 58: 803-805
    CrossrefPubMedGoogle Scholar
  • 37 Wilder RB, Schlembach PJ, Jones D et al. European Organization for Research and Treatment of Cancer and Groupe d’Etude des Lymphomes de l’Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer 2002; 94: 1731-1738
    CrossrefPubMedGoogle Scholar
  • 38 Wirth A, Yuen K, Barton M et al. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer 2005; 104: 1221-1229
    CrossrefPubMedGoogle Scholar
  • 39 Xing KH, Connors JM, Lai A et al. Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis. Blood 2014; 123: 3567-3573
    CrossrefPubMedGoogle Scholar